1. Home
  2. ADXN vs PRPO Comparison

ADXN vs PRPO Comparison

Compare ADXN & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addex Therapeutics Ltd

ADXN

Addex Therapeutics Ltd

N/A

Current Price

$7.83

Market Cap

10.0M

Sector

Health Care

ML Signal

N/A

Logo Precipio Inc.

PRPO

Precipio Inc.

N/A

Current Price

$23.50

Market Cap

32.4M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
ADXN
PRPO
Founded
2002
N/A
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
32.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ADXN
PRPO
Price
$7.83
$23.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.0K
10.1K
Earning Date
12-04-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$198,824.00
$22,800,000.00
Revenue This Year
$86.57
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.95
52 Week Low
$6.51
$3.90
52 Week High
$12.05
$28.50

Technical Indicators

Market Signals
Indicator
ADXN
PRPO
Relative Strength Index (RSI) 47.30 50.72
Support Level $7.01 $24.00
Resistance Level $8.30 $25.03
Average True Range (ATR) 0.43 1.32
MACD 0.02 -0.29
Stochastic Oscillator 41.41 35.65

Price Performance

Historical Comparison
ADXN
PRPO

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: